



- (51) **International Patent Classification:**
A61K 31/137 (2006.01) *A61P 25/18* (2006.01)
- (21) **International Application Number:**
PCT/PL2012/050014
- (22) **International Filing Date:**
30 May 2012 (30.05.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
P.395112 3 June 2011 (03.06.2011) PL
- (71) **Applicant** (for all designated States except US): **STO-WARZYSZENIE ŚW. CELESTYNA** [PL/PL];
Mikoszów 27, PL-57-100 Strzelin (PL).
- (72) **Inventor; and**
- (71) **Applicant** : **KOBEL-BUYS, Krystyna** [PL/PL]; ul.
Wojska Polskiego 5/1, PL-57-100 Strzelin (PL).
- (74) **Agents:** **CHLEBICKA, Lidia** et al.; BRANDPAT Patent
and Trademark Attorneys, Chlebicka Czyż Gałązkiewicz
Ziółkowski PP, Hoża str. 29/31 Apt.31, PL-00-521 Warsz-
awa (PL).
- (81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).
- Published:**
- with international search report (Art. 21(3))
 - with amended claims (Art. 19(1))

(54) **Title:** CLENBUTEROL FOR USE IN TREATMENT OF AUTISM

(57) **Abstract:** Clenbuterol or its salt for use in the treatment of autism, in particular pediatric autism. Improved contact with surroundings, better concentration, improved ability to plan a specific task, improved understanding, calming, and reduced psychomotor anxiety were observed.



WO 2012/165984 A1

Clenbuterol for use in treatment of autism

The invention relates to clenbuterol for a new use in treatment of autism, in particular pediatric autism.

5 Studies in children indicate that the autism spectrum is a moderately frequent, heterogeneous range of conditions classified as pervasive developmental disorders, present in 3-6 per 1,000 live-born children. Autism is characterized by abnormalities in 3 domains: 1. social integration,
10 2. language, communication and play, 3. scope of interests and activities. These developmental disorders pose a major social problem. An increasing incidence of autism in recent years has stimulated research on new treatment options for this syndrome. Pedagogic, psychological and speech therapy
15 methods constitute an essential part of the therapy, while psychomotoric and sensomotoric methods are supplementary. Recent years have seen a progress in research on pharmacological methods of treatment of autism and its symptoms. Studies focused on administration of medications
20 which proved effective in treatment of certain symptoms and behaviors observed also in people with autism, such as attention disorders, anxiety, and hyperactivity. Medications applied were selective monoamines reuptake inhibitors (clomipramine, fluvoxamine, fluoxetine,
25 paroxetine and sertraline), used in treatment of certain symptoms coexisting with autism, such as depression, anxiety, and obsessive-compulsive activities.

Over recent years the most commonly investigated medications in the context of treatment of autism were
30 antipsychotics which reduce hyperactivity, stereotyped

behaviors, withdrawal and aggression in autistic children. The most commonly used medications in this group include aripiprazole, risperidone and olanzapine. Unfortunately, just like antidepressants, these medications produce
5 adverse effects, including reduced activity and sedation.

Stimulants were also used in order to decrease hyperactivity of autistic children; however, contrary adverse effects were often observed.

Patent application US2005222272 reveals a method of
10 treatment of autism, including administration of an effective amount of a medication described as NMDA (N-methyl-D-aspartate activated) receptor antagonist or its pharmaceutically acceptable salt, preferably at doses from about 1 mg to about 100 mg daily. Application of several
15 compounds of this group improved frontal executive functions related to symptoms of autism, including speech expression, and reduced perseveration.

Patent application US20100130566 concerns treatment of autism spectrum disorder (ASD), including autism, using
20 agents activating locus coeruleus-noradrenergic (LC-NA) system in the brain. However, no examples of specific effects of this treatment are provided in the document.

Unexpectedly, it turned out that administration of
25 effective amounts of clenbuterol or its pharmaceutically effective salt seems to practically alleviate functional disorders related to ASD. In addition, no adverse effects associated with medications previously used in treatment of autism were observed with a long-term administration of
30 clenbuterol or its pharmaceutically acceptable salt.

Clenbuterol ((*RS*)-1-(4-amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethanol) is a β_2 -adrenergic receptor agonist. When present in the blood, it stimulates adrenergic receptors in muscles and increases metabolism of carbohydrates and fats as well as metabolism and synthesis of proteins in striated muscles. Apart from its known (and applied in treatment) activity on smooth muscles of the bronchial tree and blood vessels, clenbuterol increases the mass and strength of muscles.

In recent years, central neuroprotective activity of this β_2 -adrenomimetic has been confirmed in children with central movement disorders in the course of cerebral palsy. The effects of clenbuterol on the central nervous system include modulation of neurotransmitters, regulation of cell metabolism and stabilization of cell membranes. In this way it may improve certain neuropsychological disorders.

The aim of this invention is to provide an efficacious and safe method of alleviation and treatment of autistic symptoms, free of adverse effects.

The subject of the invention is clenbuterol or its pharmaceutically acceptable salt for use in the treatment of symptoms of autism, in particular pediatric autism. The most commonly used salt of clenbuterol is its hydrochloride.

Treated symptoms of autism include a lack of contact with surroundings, poor understanding, a lack of concentration and ability to plan, speech and attention disorders, and psychomotor anxiety.

Preferably, clenbuterol or its salt is used in an oral or inhaled formulation. Preferable oral formulations

include tablets, powder, granules, pellets, capsules, solution, and syrup.

According to the invention, clenbuterol or its salt is administered at a daily dose from 0.1 to 1.5 µg per
5 kilogram of the patient's bodyweight, preferably at a daily dose from 0.2 µg to 1.2 µg per kilogram of the patient's bodyweight, preferably at a daily dose from 0.2 µg to 0.5 µg per kilogram of the patient's bodyweight.

The daily dose of clenbuterol or its salt may be
10 administered as one dose or divided into two doses.

In order to achieve optimum results, clenbuterol or its salt is administered for a period from 1 to 24 months, preferably from 3 to 12 months.

The method of control and alleviation of autistic
15 symptoms according to the invention comprises administration of an effective amount of clenbuterol or its pharmaceutically acceptable salt, preferably hydrochloride, to the patient. Clenbuterol is administered orally or inhaled; preferably, oral formulation is selected from the
20 following: tablets, powder, granules, pellets, capsules, solution, or syrup.

In the method of the invention, clenbuterol or its salt is administered at a daily dose from 0.1 to 1.5 µg per kilogram of the patient's bodyweight, preferably at a daily
25 dose from 0.2 µg to 1.2 µg per kilogram of the patient's bodyweight, preferably at a daily dose from 0.2 µg to 0.5 µg per kilogram of the patient's bodyweight. These doses are different from hitherto applied doses of clenbuterol.

In the method of the invention, the medication is administered in one or two doses per day. Clenbuterol or its salt is administered for a period from 1 to 24 months, preferably from 3 to 12 months.

5

New use of clenbuterol or its salts in production of a medication for treatment of autistic symptoms in preferred embodiments is presented in more detail in the following examples.

10

Examples:

Example 1

A 4-year old patient with autistic symptoms in the form of disorders of social integration, verbal and non-verbal communication, play disorders and concomitant anxiety, especially when changing environment, was administered clenbuterol at a dose of $\frac{1}{4}$ tablet containing 20 μg of clenbuterol once daily for a period of 3 months. After application of the therapy the increased interest in the environment was observed; the child's contact with surroundings improved and its anxiety symptoms decreased.

20

Example 2

A 7-year old patient with pediatric autism and cerebral palsy was administered the medication at a dose of $\frac{1}{4}$ of 20 μg tablet twice daily for a period of 12 months. The applied treatment resulted in improvement with respect to understanding, concentration, attention, and speech.

25

30 Example 3

A 9-year old patient with early pediatric autism, psychomotor hyperactivity syndrome and speech development delay was administered clenbuterol at a dose of $\frac{1}{2}$ of 20 μ g tablet once daily for a period of 12 months. Improvement in
5 speech expression was achieved as well as reduction of psychomotor anxiety and grimacing.

It has been assumed that clenbuterol, modulating the brain neurotransmitter systems, affects also the endocrine
10 and immunological system. As a result, alleviation of communication disorders and improved contact with surroundings is observed in autistic children. Improved contact with surroundings, better concentration, improved ability to plan a specific task, improved understanding,
15 calming, and reduced psychomotor anxiety were observed during administration of clenbuterol at very small doses to autistic children.

Claims

1. Clenbuterol or its pharmaceutically acceptable salt for use in the treatment of symptoms of autism, in particular
5 pediatric autism.

2. Clenbuterol or its pharmaceutically acceptable salt for use in the treatment of symptoms of autism according to claim 1, wherein the salt is clenbuterol hydrochloride.
10

3. Clenbuterol or its pharmaceutically acceptable salt for use in the treatment of symptoms of autism according to claim 1 or 2, wherein the symptoms of autism include a lack of contact with surroundings, poor understanding, a lack of
15 concentration and ability to plan, speech and attention disorders, and psychomotor anxiety.

4. Clenbuterol or its pharmaceutically acceptable salt for use in the treatment of symptoms of autism according to
20 claims 1-3, wherein clenbuterol or its salt is applied in the form of a medication for inhalation or for oral administration, preferably in the form of tablets, powder, granules, pellets, capsules, solution, or syrup.

25 5. Clenbuterol or its pharmaceutically acceptable salt for use in the treatment of symptoms of autism according to claim 1-4, wherein clenbuterol or its salt is administered at a daily dose from 0.1 µg to 1.5 µg per kilogram of the patient's bodyweight.

6. Clenbuterol or its pharmaceutically acceptable salt for use in the treatment of symptoms of autism according to claim 5, wherein clenbuterol or its salt is administered at a daily dose from 0.2 µg to 1.2 µg per kilogram of the patient's bodyweight, preferably at a daily dose from 0.2 µg to 0.5 µg per kilogram of the patient's bodyweight.

7. Clenbuterol or its pharmaceutically acceptable salt for use in the treatment of symptoms of autism according to claim 1-6, wherein clenbuterol or its salt is administered in one or two doses per day.

8. Clenbuterol or its pharmaceutically acceptable salt for use in the treatment of symptoms of autism according to claim 1-7, wherein clenbuterol or its salt is administered for a period from 1 to 24 months.

9. A method of control and alleviation of autistic symptoms in a patient comprising administration of an effective amount of clenbuterol or its pharmaceutically acceptable salt, preferably clenbuterol hydrochloride.

10. The method of claim 9, wherein clenbuterol or its salt is administered orally or inhaled.

25

11. The method of claim 10, wherein clenbuterol or its salt is administered orally in the form selected from among tablets, powder, granules, pellets, capsules, solution, or syrup.

12. The method of claims 9-11, wherein clenbuterol or its salt is administered at a daily dose from 0.1 µg to 1.5 µg per kilogram of the patient's bodyweight.

- 5 13. The method of claim 12, wherein clenbuterol or its salt is administered at a daily dose from 0.2 µg to 1.2 µg per kilogram of the patient's bodyweight, preferably at a daily dose from 0.2 µg to 0.5 µg per kilogram of the patient's bodyweight.

10

14. The method of claim 12 or 13, wherein clenbuterol or its salt is administered in one or two doses per day.

- 15 15. The method of claim 9-14, wherein clenbuterol or its salt is administered for a period from 1 to 24 months.

AMENDED CLAIMS
received by the International Bureau on 24 Octobre 2012 (24.10.2012)

Claims

1. Clenbuterol or its pharmaceutically acceptable salt for use in the treatment of autism, in particular pediatric autism.
2. Clenbuterol or its pharmaceutically acceptable salt for use in the treatment of autism according to claim 1, wherein the salt is clenbuterol hydrochloride.
3. Clenbuterol or its pharmaceutically acceptable salt for use in the treatment of autism according to claim 1 or 2, wherein the symptoms of autism include a lack of contact with surroundings, poor understanding, a lack of concentration and ability to plan, speech and attention disorders, and psychomotor anxiety.
4. Clenbuterol or its pharmaceutically acceptable salt for use in the treatment of autism according to claims 1-3, wherein clenbuterol or its salt is applied in the form of a medication for inhalation or oral administration, preferably in the form of tablets, powder, granules, pellets, capsules, solution, or syrup.
5. Clenbuterol or its pharmaceutically acceptable salt for use in the treatment of autism according to claim 1-4, wherein clenbuterol or its salt is administered at a daily dose from 0.1 µg to 1.5 µg per kilogram of the patient's bodyweight.
6. Clenbuterol or its pharmaceutically acceptable salt for use in the treatment of autism according to claim 5, wherein

clenbuterol or its salt is administered at a daily dose from 0.2 µg to 1.2 µg per kilogram of the patient's bodyweight, preferably at a daily dose from 0.2 µg to 0.5 µg per kilogram of the patient's bodyweight.

7. Clenbuterol or its pharmaceutically acceptable salt for use in the treatment of autism according to claim 1-6, wherein clenbuterol or its salt is administered in one or two doses per day.

8. Clenbuterol or its pharmaceutically acceptable salt for use in the treatment of autism according to claim 1-7, wherein clenbuterol or its salt is administered for a period from 1 to 24 months.

9. A method of control and alleviation of autism in a patient comprising administration of an effective amount of clenbuterol or its pharmaceutically acceptable salt, preferably clenbuterol hydrochloride.

10. The method of claim 9, wherein clenbuterol or its salt is administered orally or inhaled.

11. The method of claim 10, wherein clenbuterol or its salt is administered orally in the form selected from among tablets, powder, granules, pellets, capsules, solution, or syrup.

12. The method of claims 9-11, wherein clenbuterol or its salt is administered at a daily dose from 0.1 µg to 1.5 µg per kilogram of the patient's bodyweight.

13. The method of claim 12, wherein clenbuterol or its salt is administered at a daily dose from 0.2 µg to 1.2 µg per kilogram of the patient's bodyweight, preferably at a daily dose from 0.2 µg to 0.5 µg per kilogram of the patient's bodyweight.

14. The method of claim 12 or 13, wherein clenbuterol or its salt is administered in one or two doses per day.

15. The method of claim 9-14, wherein clenbuterol or its salt is administered for a period from 1 to 24 months.

INTERNATIONAL SEARCH REPORT

International application No
PCT/PL2012/050014

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K31/137 A61P25/18
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data, BIOSIS, EMBASE, SCISEARCH, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FINNEGAN K T ET AL: "A COMPARISON OF THE NEUROCHEMICAL AND BEHAVIORAL EFFECTS OF CLENBUTEROL AND DESIPRAMINE", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 134, no. 2, 1987, pages 131-136, XP25555171, ISSN: 0014-2999 abstract page 132, column 1, paragraph 3 page 135, column 2, paragraph 2 ----- -/--	1,2,7,9,14



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

14 August 2012

Date of mailing of the international search report

27/08/2012

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Cielen, Elsie

INTERNATIONAL SEARCH REPORT

International application No

PCT/PL2012/050014

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BRZECKI A: "Establishing a basis for clenbuterol treatment of some diseases of the CNS", NEW MEDICINE 2003 PL, vol. 6, no. 1, 2003, pages 29-34, XP008154122, ISSN: 1427-0994	1,3,9
Y	abstract page 5, paragraph 14 - page 6, paragraph 5 -----	1-15
Y	US 2010/130566 A1 (PURPURA DOMINICK P [US] ET AL) 27 May 2010 (2010-05-27) cited in the application page 1, paragraphs [0007], [0010]-[0012] claims 1, 2, 3, 5, 6 -----	1-15
Y	US 2008/014152 A1 (DI MAURO THOMAS M [US] ET AL) 17 January 2008 (2008-01-17) page 1, paragraph [0005] page 2, paragraphs [0015]-[0016], [0020] claims 1-3 -----	4-7,10, 12,13
A	WO 2008/095253 A1 (GOSFORTH CT HOLDINGS PTY LTD [AU]; BIRD PHILIP [AU]) 14 August 2008 (2008-08-14) page 1, lines 4-10 page 8, lines 15-19 page 12, lines 7-23 page 17, lines 10-12 page 21, lines 8-11 page 22, line 12 page 23, line 3 -----	1-15
A	WO 01/68137 A2 (UNIV BROWN RES FOUND [US]; HUGHES HOWARD MED INST [US]; ALBERINI CRIST) 20 September 2001 (2001-09-20) page 3, lines 13-17 page 4, lines 10-12 page 5, lines 25-30 page 20, lines 9-16 page 29, lines 3-6 page 31, lines 1-7 page 58, lines 28-32 claims 1, 13 figure 2 -----	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/PL2012/050014

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2010130566	A1	27-05-2010	NONE
US 2008014152	A1	17-01-2008	NONE
WO 2008095253	A1	14-08-2008	AU 2007346591 A1 14-08-2008
		EP 2129369 A1 09-12-2009	
		JP 2010518027 A 27-05-2010	
		US 2010087422 A1 08-04-2010	
		WO 2008095221 A1 14-08-2008	
		WO 2008095253 A1 14-08-2008	
WO 0168137	A2	20-09-2001	AU 4363501 A 24-09-2001
		WO 0168137 A2 20-09-2001	